Kyowa Hakko Kirin Co., Limited

Kirin Holdings Kabushiki Kaisha

Aurox, LLC

Philippe Collas

James M Robl

Eddie Sullivan

Isao Ishida

Kazuma Tomizuka

Yoshimi Kuroiwa

Barbara A Osborne

Richard A Goldsby

Poothappillai Kasinathan

Poothappillai K Kasinathan

Bjorn Steen Skalhegg

Kasinathan P

P Kasinathan

The invention features novel methods for the production of large quantities of xenogenous antibodies, such as human antibodies. Preferably, this result is effected by inactivation of IgM heavy chain expression and, optionally, by inactivation of Ig light chain expression, and by the further introduction of an artificial chromosome which results in the expression of xenogenous antibodies (e.g., non-bovine antibodies), preferably human antibodies.

Transgenic ungulates capable of human antibody production

The invention provides methods for altering the expression profile of a cell to convert the cell from one cell type to a desired cell type. These reprogrammed cells may be used in a variety of medical applications for treating a mammal in need of a particular cell type.

Methods for altering cell fate

The invention provides methods for altering the expression profile of a cell to convert the cell from one cell type to a desired cell type (e.g., T-cells). These reprogrammed cells may be used in a variety of medical applications for treating a mammal in need of a particular cell type.

Methods for altering cell fate to generate T-cells specific for an antigen of interest

The invention provides methods for cloning mammals that allow the donor chromosomes or donor cells to be reprogrammed prior to insertion into an enucleated oocyte. The invention also features methods of inserting chromosomes or nuclei into recipient cells.

Methods for cloning non-human mammals using reprogrammed donor chromatin or donor cells

Growing community of inventors

Oslo, Norway

Philippe Collas